{
    "info": {
        "nct_id": "NCT04701307",
        "official_title": "Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)",
        "inclusion_criteria": "* Participant must have unresected or locally advanced small cell lung cancer (Cohort 1) or high-grade neuroendocrine carcinoma (Cohort 2) confirmed by staff pathologist. High-grade neuroendocrine carcinoma of prostate (e.g. aggressive variant prostate cancer, small cell of prostate, etc.) are excluded\n* Patients must have had at least one prior line of systemic therapy directed at their malignancy\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 1\n* Participant must be >= 18 years of age\n* Absolute neutrophil count >= 1,500/uL\n* Platelets >= 100,000/uL\n* Hemoglobin >= 9 g/dL\n* Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance >= 60 mL/min using the Cockcroft-Gault equation\n* Total bilirubin =< 1.5 x ULN (=< 2.0 in patients with known Gilberts syndrome) OR direct bilirubin =< 1 x ULN\n* Aspartate aminotransferase and alanine aminotransferase =< 2.5 x ULN unless liver metastases are present, in which case they must be =< 5 x ULN\n* International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n* Participant receiving corticosteroids may continue as long as their dose equivalent to 10 mg prednisone or less and is stable for least 4 weeks prior to initiating protocol therapy\n* Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment\n* Female participant has a negative serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential and agrees use an adequate method of contraception from screening through 180 days after the last dose of study treatment, or is of nonchildbearing potential. Nonchildbearing potential is defined as follows (by other than medical reasons):\n\n  * >= 45 years of age and has not had menses for > 1 year\n  * Patients who have been amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation\n  * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use an adequate barrier method throughout the study, starting with the screening visit through 180 days after the last dose of study treatment. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient\n  * Pelvic irradiation\n* Participant must agree to not breastfeed during the study or for 180 days after the last dose of study treatment\n* Male participant agrees to use an adequate method of contraception starting with the first dose of study treatment through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient\n* Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Participant must not be simultaneously enrolled in any interventional clinical trial\n* Participant must not have previously received a simultaneous combination of PARP inhibitor and immune checkpoint blockade (immunotherapy)\n* Participant must not have had major surgery =< 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects\n* Participant must not have received investigational therapy =< 4 weeks prior initiating protocol therapy\n* Participant has had radiation therapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapy\n* Participant must not have a known hypersensitivity to niraparib and dostarlimab components or excipients\n* Participant must not have received a transfusion (platelets or red blood cells) =< 4 weeks prior to initiating protocol therapy\n* Participant must not have received colony-stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy\n* Participant has had any known grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment\n* Participant must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)\n* Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent\n* Participant must not have had diagnosis, detection, or treatment of another type of cancer =< 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated)\n* Participant must not have known, symptomatic brain or leptomeningeal metastases. Patients should have magnetic resonance imaging (MRI) brain with and without contrast (or computed tomography [CT] head with and without contrast) within 4 weeks prior to initiation of therapy. If history of known brain metastases, these must be treated with completion of treatment at least two weeks prior to initiation of therapy. Known brain metastases must be clinically stable and asymptomatic\n* Patient experienced >= grade 3 immune-related adverse event (AE) with prior immunotherapy\n* Participant has a diagnosis of immunodeficiency or has received systemic steroid therapy in excess of 10 mg prednisone (or equivalent) or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy\n* Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected)\n* Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Participant must not have a history of interstitial lung disease\n* Participant has received a live vaccine within 14 days of initiating protocol therapy",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Female participant has a negative serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential and agrees use an adequate method of contraception from screening through 180 days after the last dose of study treatment, or is of nonchildbearing potential. Nonchildbearing potential is defined as follows (by other than medical reasons):",
            "criterions": [
                {
                    "exact_snippets": "Female participant",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "negative serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before study treatment"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "if of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees use an adequate method of contraception from screening through 180 days after the last dose of study treatment",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from screening through 180 days after the last dose of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "is of nonchildbearing potential. Nonchildbearing potential is defined as follows (by other than medical reasons):",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "nonchildbearing potential"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must have unresected or locally advanced small cell lung cancer (Cohort 1) or high-grade neuroendocrine carcinoma (Cohort 2) confirmed by staff pathologist. High-grade neuroendocrine carcinoma of prostate (e.g. aggressive variant prostate cancer, small cell of prostate, etc.) are excluded",
            "criterions": [
                {
                    "exact_snippets": "unresected or locally advanced small cell lung cancer (Cohort 1)",
                    "criterion": "small cell lung cancer",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "unresected",
                                "locally advanced"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "high-grade neuroendocrine carcinoma (Cohort 2)",
                    "criterion": "high-grade neuroendocrine carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed by staff pathologist",
                    "criterion": "diagnosis confirmation by staff pathologist",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "High-grade neuroendocrine carcinoma of prostate (e.g. aggressive variant prostate cancer, small cell of prostate, etc.) are excluded",
                    "criterion": "high-grade neuroendocrine carcinoma of prostate",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have had at least one prior line of systemic therapy directed at their malignancy",
            "criterions": [
                {
                    "exact_snippets": "at least one prior line of systemic therapy directed at their malignancy",
                    "criterion": "prior lines of systemic therapy for malignancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >= 1,500/uL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >= 1,500/uL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100,000/uL",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000/uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent",
            "criterions": [
                {
                    "exact_snippets": "able to understand the study procedures",
                    "criterion": "ability to understand study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to participate in the study by providing written informed consent",
                    "criterion": "provision of written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of =< 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x ULN (=< 2.0 in patients with known Gilberts syndrome) OR direct bilirubin =< 1 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x ULN (=< 2.0 in patients with known Gilberts syndrome)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (Gilberts syndrome)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.0,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin =< 1 x ULN",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase and alanine aminotransferase =< 2.5 x ULN unless liver metastases are present, in which case they must be =< 5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase ... =< 2.5 x ULN unless liver metastases are present, in which case they must be =< 5 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase ... =< 2.5 x ULN unless liver metastases are present, in which case they must be =< 5 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pelvic irradiation",
            "criterions": [
                {
                    "exact_snippets": "Pelvic irradiation",
                    "criterion": "pelvic irradiation",
                    "requirements": [
                        {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male participant agrees to use an adequate method of contraception starting with the first dose of study treatment through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient",
            "criterions": [
                {
                    "exact_snippets": "Male participant",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to use an adequate method of contraception starting with the first dose of study treatment through 180 days after the last dose of study treatment",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Abstinence is acceptable if this is the established and preferred contraception for the patient",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "acceptable methods",
                            "expected_value": [
                                "abstinence",
                                "other adequate methods"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment",
                    "criterion": "blood donation",
                    "requirements": [
                        {
                            "requirement_type": "prohibition period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "donations"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 0,
                                        "unit": "donations"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial",
            "criterions": [
                {
                    "exact_snippets": "Human immunodeficiency virus (HIV)-infected patients",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on effective anti-retroviral therapy",
                    "criterion": "anti-retroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable viral load within 6 months",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use an adequate barrier method throughout the study, starting with the screening visit through 180 days after the last dose of study treatment. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient",
            "criterions": [
                {
                    "exact_snippets": "Post-hysterectomy",
                    "criterion": "hysterectomy status",
                    "requirements": [
                        {
                            "requirement_type": "history of hysterectomy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "post-bilateral oophorectomy",
                    "criterion": "bilateral oophorectomy status",
                    "requirements": [
                        {
                            "requirement_type": "history of bilateral oophorectomy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "post-tubal ligation",
                    "criterion": "tubal ligation status",
                    "requirements": [
                        {
                            "requirement_type": "history of tubal ligation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound.",
                    "criterion": "confirmation of hysterectomy or oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "medical records of the actual procedure",
                                "ultrasound"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Tubal ligation must be confirmed with medical records of the actual procedure",
                    "criterion": "confirmation of tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "medical records of the actual procedure"
                        }
                    ]
                },
                {
                    "exact_snippets": "otherwise the patient must be willing to use an adequate barrier method throughout the study, starting with the screening visit through 180 days after the last dose of study treatment.",
                    "criterion": "contraception use (if no tubal ligation)",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use barrier contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "screening visit"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 180,
                                        "unit": "days after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Abstinence is acceptable if this is the established and preferred contraception for the patient",
                    "criterion": "contraception method (abstinence)",
                    "requirements": [
                        {
                            "requirement_type": "abstinence as contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have been amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation",
            "criterions": [
                {
                    "exact_snippets": "Patients who have been amenorrhoeic for < 2 years",
                    "criterion": "amenorrhoea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without history of a hysterectomy",
                    "criterion": "history of hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "without ... oophorectomy",
                    "criterion": "history of oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation",
                    "criterion": "follicle stimulating hormone value",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "postmenopausal range"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant receiving corticosteroids may continue as long as their dose equivalent to 10 mg prednisone or less and is stable for least 4 weeks prior to initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Participant receiving corticosteroids may continue as long as their dose equivalent to 10 mg prednisone or less",
                    "criterion": "corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "dose ... is stable for least 4 weeks prior to initiating protocol therapy",
                    "criterion": "corticosteroid dose stability",
                    "requirements": [
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* >= 45 years of age and has not had menses for > 1 year",
            "criterions": [
                {
                    "exact_snippets": ">= 45 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not had menses for > 1 year",
                    "criterion": "menses",
                    "requirements": [
                        {
                            "requirement_type": "absence_duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants",
                    "criterion": "INR or PT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                },
                {
                    "exact_snippets": "Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
                    "criterion": "aPTT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance >= 60 mL/min using the Cockcroft-Gault equation",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance >= 60 mL/min using the Cockcroft-Gault equation",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must agree to not breastfeed during the study or for 180 days after the last dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Participant must agree to not breastfeed during the study or for 180 days after the last dose of study treatment",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "breastfeeding events during the study and for 180 days after last dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must be >= 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "Participant must be >= 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Participant must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)",
            "criterions": [
                {
                    "exact_snippets": "must not have any known history of myelodysplastic syndrome (MDS)",
                    "criterion": "history of myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have any known history of ... acute myeloid leukemia (AML)",
                    "criterion": "history of acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has a diagnosis of immunodeficiency or has received systemic steroid therapy in excess of 10 mg prednisone (or equivalent) or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "received systemic steroid therapy in excess of 10 mg prednisone (or equivalent) ... within 7 days prior to initiating protocol therapy",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone (or equivalent)"
                            }
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to initiating protocol therapy"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to initiating protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has had radiation therapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "radiation therapy encompassing > 20% of the bone marrow within 2 weeks",
                    "criterion": "radiation therapy to bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "extent",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "% of the bone marrow"
                            }
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any radiation therapy within 1 week prior to day 1 of protocol therapy",
                    "criterion": "any radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have a history of interstitial lung disease",
            "criterions": [
                {
                    "exact_snippets": "must not have a history of interstitial lung disease",
                    "criterion": "history of interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have a known hypersensitivity to niraparib and dostarlimab components or excipients",
            "criterions": [
                {
                    "exact_snippets": "must not have a known hypersensitivity to niraparib",
                    "criterion": "hypersensitivity to niraparib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have a known hypersensitivity to ... dostarlimab components or excipients",
                    "criterion": "hypersensitivity to dostarlimab components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient experienced >= grade 3 immune-related adverse event (AE) with prior immunotherapy",
            "criterions": [
                {
                    "exact_snippets": "experienced >= grade 3 immune-related adverse event (AE) with prior immunotherapy",
                    "criterion": "immune-related adverse event with prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have received colony-stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "must not have received colony-stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy",
                    "criterion": "colony-stimulating factor administration",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have known, symptomatic brain or leptomeningeal metastases. Patients should have magnetic resonance imaging (MRI) brain with and without contrast (or computed tomography [CT] head with and without contrast) within 4 weeks prior to initiation of therapy. If history of known brain metastases, these must be treated with completion of treatment at least two weeks prior to initiation of therapy. Known brain metastases must be clinically stable and asymptomatic",
            "criterions": [
                {
                    "exact_snippets": "Participant must not have known, symptomatic brain or leptomeningeal metastases",
                    "criterion": "brain or leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients should have magnetic resonance imaging (MRI) brain with and without contrast (or computed tomography [CT] head with and without contrast) within 4 weeks prior to initiation of therapy",
                    "criterion": "brain imaging (MRI or CT)",
                    "requirements": [
                        {
                            "requirement_type": "performed_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of therapy"
                            }
                        },
                        {
                            "requirement_type": "contrast",
                            "expected_value": [
                                "with",
                                "without"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "If history of known brain metastases, these must be treated with completion of treatment at least two weeks prior to initiation of therapy",
                    "criterion": "treatment of known brain metastases (if present)",
                    "requirements": [
                        {
                            "requirement_type": "treatment_completed_before",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks prior to initiation of therapy"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Known brain metastases must be clinically stable and asymptomatic",
                    "criterion": "known brain metastases (if present)",
                    "requirements": [
                        {
                            "requirement_type": "clinical_stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment",
            "criterions": [
                {
                    "exact_snippets": "Participant has an active autoimmune disease",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)",
                    "criterion": "systemic treatment for autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "disease-modifying agents",
                                "corticosteroids",
                                "immunosuppressive drugs"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent",
            "criterions": [
                {
                    "exact_snippets": "serious, uncontrolled medical disorder",
                    "criterion": "serious, uncontrolled medical disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "nonmalignant systemic disease",
                    "criterion": "nonmalignant systemic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active, uncontrolled infection",
                    "criterion": "active, uncontrolled infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled ventricular arrhythmia",
                    "criterion": "uncontrolled ventricular arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "recent (within 90 days) myocardial infarction",
                    "criterion": "recent myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled major seizure disorder",
                    "criterion": "uncontrolled major seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable spinal cord compression",
                    "criterion": "unstable spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "superior vena cava syndrome",
                    "criterion": "superior vena cava syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any psychiatric disorder that prohibits obtaining informed consent",
                    "criterion": "psychiatric disorder prohibiting informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has received a live vaccine within 14 days of initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Participant has received a live vaccine within 14 days of initiating protocol therapy",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relative to event",
                            "expected_value": "initiating protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have previously received a simultaneous combination of PARP inhibitor and immune checkpoint blockade (immunotherapy)",
            "criterions": [
                {
                    "exact_snippets": "must not have previously received a simultaneous combination of PARP inhibitor and immune checkpoint blockade (immunotherapy)",
                    "criterion": "prior treatment with simultaneous combination of PARP inhibitor and immune checkpoint blockade",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have had major surgery =< 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects",
            "criterions": [
                {
                    "exact_snippets": "must not have had major surgery =< 3 weeks prior to initiating protocol therapy",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participant must have recovered from any surgical effects",
                    "criterion": "recovery from surgical effects",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have received a transfusion (platelets or red blood cells) =< 4 weeks prior to initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "must not have received a transfusion (platelets or red blood cells) =< 4 weeks prior to initiating protocol therapy",
                    "criterion": "transfusion (platelets or red blood cells)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks prior to initiating protocol therapy"
                            }
                        },
                        {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not be simultaneously enrolled in any interventional clinical trial",
            "criterions": [
                {
                    "exact_snippets": "must not be simultaneously enrolled in any interventional clinical trial",
                    "criterion": "simultaneous enrollment in interventional clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have received investigational therapy =< 4 weeks prior initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "must not have received investigational therapy =< 4 weeks prior initiating protocol therapy",
                    "criterion": "receipt of investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have had diagnosis, detection, or treatment of another type of cancer =< 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated)",
            "criterions": [
                {
                    "exact_snippets": "must not have had diagnosis, detection, or treatment of another type of cancer =< 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated)",
                    "criterion": "history of another type of cancer",
                    "requirements": [
                        {
                            "requirement_type": "absence within time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated",
                    "criterion": "history of basal or squamous cell carcinoma of the skin or definitively treated cervical cancer",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from restriction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected)",
            "criterions": [
                {
                    "exact_snippets": "known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "marker",
                            "expected_value": "hepatitis B surface antigen (HBsAg) reactive"
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected)",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "marker",
                            "expected_value": "hepatitis C virus (HCV) ribonucleic acid detected"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has had any known grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment",
            "criterions": [
                {
                    "exact_snippets": "grade 3 or 4 anemia ... due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "prior chemotherapy"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation_to_treatment",
                            "expected_value": "most recent treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 3 or 4 neutropenia ... due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment",
                    "criterion": "neutropenia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "prior chemotherapy"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation_to_treatment",
                            "expected_value": "most recent treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 3 or 4 thrombocytopenia ... due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment",
                    "criterion": "thrombocytopenia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "prior chemotherapy"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation_to_treatment",
                            "expected_value": "most recent treatment"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}